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THE CENTRE FOR HEALTH ECONOMICS RESEARCH AND EVALUATION 
(CHERE) was established in 1991.  CHERE is a centre of excellence in health 
economics and health services research.  CHERE is funded by NSW Health under a 
Research and Development Infrastructure Grant, with additional support from Central 
Sydney Area Health Service and funding from external research.  It is an affiliated 
research unit of the Faculty of Medicine, The University of Sydney.  The centre aims to 
contribute to the development and application of health economics through research, 
teaching and policy support. 
 
CHERE’s research program encompasses both the theory and application of health 
economics.  The main theoretical research theme pursues valuing benefits, including 
understanding what individuals value from health and health care, how such values 
should be measured, and exploring the social values attached to these benefits.  The 
applied research focuses on economic and the appraisal of new programs or new ways 
of delivering and/or funding services. 
 
CHERE’s teaching includes introducing clinicians, health services managers, public 
health professionals and others to health economic principles.  Training programs aim to 
develop practical skills in health economics and health services research. 
 
Policy support is provided at all levels of the health care system by undertaking 
commissioned projects, through the provision of formal and informal advice as well as 
participation in working parties and committees. 
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This report was written and submitted to NSW Health Department in January 2000. 
Since this time circumstances relating to PET may have changed considerably. In 
particular, the costs cited in this report may have altered. The cost estimates prepared 
for the report have been re-estimated using 1998/99 and1999/00 costs, but this does not 
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1. INTRODUCTION 
 
This report is a review of the clinical uses, impacts on clinical management, clinical outcome and 
resource use of Positron Emission Tomography (PET) at Royal Prince Alfred Hospital (RPAH). 
PET is a relatively new and resource intensive diagnostic technology which has a range of clinical 
applications, particularly in surgical oncology, neurology and cardiology (although the latter has 
become less important over time).  At present there is only limited information on the clinical 
effectiveness and cost-effectiveness of the technology compared with other diagnostic 
technologies. 
 
Specifically, PET is a functional imaging modality which is able to quantify physiological and 
biochemical processes in-vivo in humans, using short-lived radioisotopes called positron emitters. 
PET radioisotopes are produced by particle accelerators.  PET uses the tracer method and image 
reconstruction techniques to provide a three dimensional depiction of metabolic events. 
 
PET was initially introduced in the 1970s, but was primarily seen as a research tool with only 
limited clinical application.  In the late 1980s and early 1990s there was increasing attention to the 
potential role of PET in a range of clinical applications.  More recently, PET has been approved 
for Medicare reimbursement in the USA (in November 1997), specifically for imaging of lung 
nodules and staging of lung cancer.   
 
PET was introduced in 1992 in Sydney at RPAH and in Melbourne at the Austin and Repatriation 
Medical Centre (ARMC). Since this time another two PET scanners have commenced operation at 
the Peter MacCullum Cancer Institute (1996) and the Wesley Hospital (1998). The PET unit at 
RPAH has now scanned over 6000 patients, with annual throughput increasing consistently since 
the unit commenced operation. Initially the emphasis was on cardiology and neurology scans.  
However, the majority of scans are now in oncology. 
 
Since 1997 there has been limited Medicare reimbursement for PET scans undertaken at RPAH 
and ARMC.  However, as yet, there has been only limited evaluation of the uses of PET and its 
impact on clinical management in Australia. CHERE has been commissioned by the NSW 
Department of Health to work with the PET unit at RPAH to undertake an evaluation of the role of 
the unit.  The initial step in the process of this evaluation was to identify the scope and key Review of Positron Emission Tomography 
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components of a comprehensive evaluation.  In particular, two approaches to evaluation were 
identified as being necessary: 
•  Retrospective analysis, addressing the range of clinical applications of PET, the throughput 
of the Unit, the costs of undertaking a PET scan for different patient groups, and the impact 
of PET on patient outcomes; and 
•  Prospective analysis, addressing the impact of PET in specific identified applications, to 
provide an unbiased assessment of the impact of PET on clinical management, outcomes for 
patients and resource use. 
 
Both components are seen as necessary to a comprehensive evaluation.  The retrospective analysis 
is important in assessing how the role of PET has changed and in providing an overview of the 
role of PET.  However, retrospective analyses are limited in that they are subject to a range of 
confounding factors, most importantly, there may be bias in the way patients were selected for 
PET scanning.  Thus, the overall evaluation strategy has incorporated both components.  The 
project commissioned by the NSW Department of Health was to undertake the retrospective 
analysis of throughput, costs and the outcomes of PET scans.  In addition, CHERE, together with 
clinicians from Royal Prince Alfred Hospital developed an NHMRC project application to 
undertake a prospective evaluation of the role of PET in management of non-small cell lung 
cancer (NSCLC), which is one of the major current clinical applications of PET at RPAH.  The 
prospective evaluation took the form of a randomised controlled trial incorporating economic 
evaluation.  The project application was successful and recruitment for the trial commenced in 
April 1999, and was completed in December 2000. Follow-up of patients is continuing until 
December 2001.   
 
This report presents the findings of the retrospective analysis of the role of the PET unit, 
particularly:   
•  Review of Australian and international literature on effectiveness and cost-effectiveness of 
PET compared with other diagnostic technologies, particularly for oncology; 
•  Summary of patient throughput, characteristics and reasons for scans for the period 1992-
1998; 
•  Detailed analysis of reasons for scans for the period 1997-98; 
•  Estimated total and average costs for the PET unit, based on costing information for the 
period 1997-98. Viney, Lowin, Pollicino, Haywood & Fulham 
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2 Literature  Review 
 
In this section we briefly review the Australian and international literature evaluating the role of 
PET in clinical and research applications.  In particular, we have focussed on the evaluation of 
PET as a diagnostic test, either as an adjunct or an alternative to existing diagnostic tests.  As 
noted, clinical and research applications for PET have emerged in three broad disease groups: 
oncology, cardiology and neurology, with the most recent emphasis in both clinical applications 
and in the evaluation literature being on oncology.  There is now a growing body of literature on 
evaluation of the role of PET in oncology, and, Robert and Milne (1999) report that more than 
70% of referrals at the majority of international clinical PET centres now come from oncology 
departments.   
 
Three recent reviews of the role of PET have been undertaken.  In 1996, a report commissioned by 
the US Veterans Health Administration was finalised which included detailed systematic reviews 
of PET in a range of oncology applications and Alzheimer’s disease (Flynn, Adams et al. 1996). 
This report found that the majority of the literature focussed on the feasibility of the use of PET 
and on diagnostic accuracy, with relatively few studies assessing efficacy or impact of PET on 
patient management.  The report concluded that, at that stage, the evaluation literature was 
relatively under-developed, and it was difficult to draw conclusions about the utility of PET.  For 
example, for diagnosis of Alzheimer’s disease, while there was good evidence to support the 
accuracy of PET, there was not yet evidence available to support more widespread use of PET in 
management of Alzheimer’s disease.  For the use of PET in diagnosis and management of cancer, 
the report concluded that the literature was even less developed.  Most studies were retrospectively 
analysed case series, with small patient numbers, lack of control groups, poor use of blinding and 
no randomisation.   
In 1999, the National Health Service Research and Development Technology Assessment 
Program published a review of the state of knowledge regarding clinical applications of PET, 
partly as a basis for determining research priorities in relation to PET in the UK (Robert and Milne 
1999). The conclusion of this report was similar to the previous US report.  In particular, the 
authors note that “there is no good evidence to suggest how PET will affect the cost-effectiveness 
of the diagnosis, prognosis and management of patients”, and they comment on the lack of large 
prospective studies.  Thus, although there were increasing numbers of studies supporting the 
diagnostic accuracy of PET in a range of conditions, there was still very little information to 
assess the utility of PET in routine clinical practice, in terms of effectiveness or cost-effectiveness. Review of Positron Emission Tomography 
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In 2000, the Department of Health and Aged Care produced a Commonwealth review of PET in 
Australia (Commonwealth Department of Health and Aged Care 2000). A key component of the 
review process was an evaluation of PET conducted by a Supporting Committee of the Medicare 
Services Advisory Committee (MSAC). MSAC explored the use of PET in six clinical indications 
including lung and colorectal cancer, coronary revascularisation, epilepsy, melanoma and glioma. 
The findings were largely consistent with the conclusions of existing reviews. It was concluded 
that there was insufficient evidence on PET’s clinical or cost effectiveness with respect to the 
clinical indications reviewed and that conclusive evidence such as a randomised controlled trial is 
needed to explore the impact of PET on clinical management.  
 
In our review of the literature we have focussed principally on the use of PET in oncology.  Given 
the relatively recent publication of the MSAC review we have not replicated their work, but have 
focussed on identifying more recent papers.  The main uses of PET in oncology identified were: 
•  Diagnosis    Differentiating between benign and malignant conditions and         
establishing the source of metastatic disease 
•  Staging    Defining the extent of disease  
•  Monitoring  Surveillance of treatment response 
•  Recurrence   Identifying recurrence 
 
The most well-established uses of PET are in staging of lung cancer and in diagnosis of solitary 
pulmonary nodules. However, because of differences in clinical practice between the USA and 
Australia, the latter is less relevant in the Australian context.  Potential uses of PET identified in 
the literature include the prediction of prognosis, tissue diagnosis and determining the best site for 
biopsy (Sarinas, Chitkara et al. 1999). 
 
The findings of our review of the literature confirmed the findings of the three previous studies. 
The key issue that needs to be emphasised in relation to the evaluation of PET is that there are 
specific challenges in evaluating a diagnostic technology.  The decision to perform a diagnostic 
test should be based on the usefulness of the information provided by the test.  In other words, it 
should provide an accurate diagnosis, support the application of a specific efficacious treatment, 
and ultimately lead to a better or more cost-effective clinical outcome for the patient.  In their 
review Robert and Milne (1999) note that Fineberg has classified three stages in the diagnostic 
process: production of a diagnostic output; the inclusion of that output into a diagnostic strategy Viney, Lowin, Pollicino, Haywood & Fulham 
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and choice of treatment; and the health outcome conditional upon treatment.  In terms of evidence 
for the value of a diagnostic test, studies which focus on technical performance and diagnostic 
accuracy are only addressing the first of these stages.  Ultimately, either prospective evaluations of 
management impact, or, at minimum, formal decision analyses based on rigorous assessment of 
sensitivity and specificity are necessary to address the second and third stages. 
 
To date, published studies have focused on defining the accuracy of PET as a diagnostic test. A 
number of prospective studies have been published, but few of these incorporate assessment of 
how PET affects clinical decision making.  There has been limited assessment of the impact of 
PET on clinical management, and virtually no assessment of the impact on patient outcomes and 
resource use.  Some studies have extrapolated from the diagnostic properties of PET to the impact 
on patient management (Wahl, Quint et al. 1994; Lowe, Fletcher et al. 1998; Weder, Schmid et al. 
1998). However, even among these studies, some authors note that they believe it would be 
unlikely that clinical management would be changed by the availability of the PET scan (Lowe, 
Fletcher et al. 1998). One recent paper, not included in either of the previous systematic reviews, 
does incorporate prospective assessment of the impact of PET on patient management, as well as 
follow-up of clinical outcomes (confirmation of diagnosis at surgery or through histology, as well 
as morbidity and mortality outcomes) (Saunders, Dussek et al. 1999). In this study 97 patients 
with confirmed or suspected resectable lung cancer were staged based on CT and conventional 
staging; CT alone; PET alone; and conventional, CT and PET.  Management decisions were based 
on all diagnostic information and patients were followed up for up to 41 months.  The study found 
that PET changed management in 37% of patients, although this figure included 15 patients for 
whom the operation was “enabled” by PET, suggesting that the inclusion criteria were not clearly 
defined.  Of the 97 patients, 15 had a planned operation cancelled as a result of the PET scan. 
 
There has been limited clinical evaluation of PET in the Australian context. A recent paper reports 
on the experience with PET at one Australian centre (Hicks, Binns et al. 1999). However, while 
the paper reports experience across a range of cancers suggesting that PET may have a role in 
changing management, the conclusions are based on case series, without clear description of the 
patient selection.  
 
Economic evaluation 
A Medline search (1990-2001; ‘positron emission tomography’ and ‘cost-benefit analysis’ 
exploded to all subheadings) was undertaken to locate papers addressing the cost-effectiveness of Review of Positron Emission Tomography 
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PET.  This was supplemented by other search strategies to locate the maximum number of papers. 
In all, 17 published economic evaluations were located, and are summarised in Table 1.  
 
While the majority of papers conclude that PET is likely to be cost saving or to fall within an 
acceptable cost-effectiveness range relative to conventional management of oncology patients, this 
conclusion must be treated with considerable caution.  All of the economic evaluations are subject 
to methodological flaws. In particular, none incorporate adequate follow-up of patient outcomes. 
Thus, even though decision tree modelling studies find that the use of PET in management of non-
small cell lung cancer results in no change or an increase in life expectancy, this is the result of an 
assumption that avoidance of surgery in this group of patients reduces mortality.  This assumption 
is not supported by any studies following up patient outcomes following incorporation of PET in 
the management strategy. In other studies there is no assessment of patient outcomes, and the 
analysis is restricted to comparison of costs based on the assumption that management will change 
and/or that patient outcomes will not be affected.  Further, most studies incorporate only limited 
assessment of the costs of alternative strategies.  More fundamentally, relative cost-effectiveness 
results are sensitive to the relative costs of procedures and it cannot be assumed that these costs 
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3  Overview of the Operation of the PET Unit 
 
3.1 Background 
The PET Unit at RPAH was established in 1992.  The PET scanner was purchased at a 
cost of approximately $5 million dollars, funded by a collaborative effort involving 
Royal Prince Alfred Hospital (RPAH), the NSW Department of Health and private 
donations.  The National Medical Cyclotron (NMC) was funded by the Commonwealth 
government, and is owned and operated by the Australian Nuclear Science and 
Technology Organisation (ANSTO).  It was established on the campus of RPAH, at a 
cost of approximately $20 million. 
 
The PET Unit began scanning in June 1992, and the annual throughput of patients in 
each year has increased consistently since then.  Over 7000 patients have now been 
scanned.  In 1999 (until November 30), 1356 studies were undertaken, comprising 400 
neurological scans, 21 cardiac scans and 935 whole body (oncology) scans. 
 
3.2 Operation of the PET Unit 
The establishment of the PET Unit and the NMC in 1992 required extensive 
refurbishment of the PET suite within the hospital, involving the floor level being raised 
and complex air-conditioning being fitted.  It also involved the installation of a rapid 
transport system under Missenden Road, to transport the PET radiotracers to the PET 
Suite. The total area of the PET Suite is 311 square metres.  Since 1992 there has been 
extensive upgrading of the computer systems of the PET unit, to improve storage and 
retrieval of data.   
 
From the outset of the PET program, RPAH has had staff members from the PET unit 
located in the NMC who are responsible for production of PET tracers for RPAH.  A 
typical production run for RPAH involves: 
•  set-up for production beginning at 0700 hrs,  
•  cyclotron irradiates PET target for 90 mins from 0730 - 0900 hrs,  
• 
18F
1 is transferred to an automated radiochemistry box and synthesis takes place over 
60 mins,  
•  a sample of the product is taken for quality control (QC) and  
•  product released 30 minutes later for human use at 1030 hrs.   
                                                 
1 
18F is a radioactive isotope with a half life of 110 minutes.  Review of Positron Emission Tomography 
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Average cyclotron beam time each week for RPA is 6 hrs.  The amount of isotope 
produced each day is variable (Figure 1), although the amount paid by RPAH is per 
vial, regardless of the amount of isotope in the vial. Multiple patient doses are possible 
from a single batch of {18F}Flurodeoxyglucose (FDG)
2, because of its 110 minute half-
life. The PET unit schedules its daily patient scanning as if an average yield will be 
available. The PET unit is advised at 1000 hrs of the amount of isotope that has been 
produced, and patients are then rescheduled accordingly.  When the yield is low patient 
numbers are maintained by limiting the extent of some studies to shorten the time for 
data acquisition.   In general, approximately 8 patients are scanned per day. 
 
Figure 1:  Daily FDG yields (in Giga Becquerels - GBqs) are shown on the vertical axes.  The marked 
fluctuations in the yield of isotope show the unreliability of production and the vulnerability of RPA 
patient scanning to poor yields.  When the yield is low patient numbers are maintained by limiting the 






















Daily FDG yield in 1998 
 
 
As soon as the isotope vial arrives in the PET unit (approximately 1030 hrs) the first 
patient is injected.  Patients are managed throughout the day to a strict time schedule 
such that as soon as one patient leaves the scanning bed another is ready to be scanned.  
The larger the area to be scanned the longer the time needed on the bed and the greater 
the quantity of active isotope required.  Most oncology studies are whole body studies 
requiring a scan from the neck to knee.  The availability of isotope only after 1030 hrs  
                                                 
2  FDG is the PET radiotracer Viney, Lowin, Pollicino, Haywood & Fulham 
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has cost implications, because most hospital activity is scheduled to occur during the 
normal working day.  PET unit staff are often required to work overtime, and patients 
are often required to be scanned in the evening. 
 
The process for each patient involves arrival at the unit followed by a consultation with 
either the PET unit director or the registrar to ensure they understand the process and to 
facilitate signing of a consent form. Patients are injected with the isotope approximately 
45 minutes prior to scanning.  Once injected, the patient is asked to remain still – this 
period is referred to as the uptake period.  Patients for whom the area scanned includes 
the pelvis are fitted with a catheter.  The duration of the scanning period is dependent 
mainly on the amount of the body to be scanned.  After the scanning has finished it 
takes approximately 2 hours for the image reconstruction techniques to provide a 3-D 
depiction of dynamic metabolic events.  The scan is assessed by the Director of the PET 
unit, and a report is sent to the referring physician.  The findings may be passed to the 
referring physician by phone in cases where surgery is booked immediately following 
the scan. 
 
The availability of the cyclotron is a limiting factor for the PET unit throughput.  The 
NMC cyclotron is closed at weekends.  It is also closed for maintenance every Monday 
and for 3 weeks over the Christmas / New Year period and for 2 weeks midyear, 
however in 1998 the midyear shutdown was not carried out. 
 
3.3 Throughput 
Table 2 summarises the annual throughput.  The current annual throughput is 
approximately 1300 patients, and this has been relatively stable over the past three 
years. Given the current arrangements for provision of the service, which involves 
supply by the NMC of a single vial of isotope per day to the Unit on 4 days of the week, 
this throughput is likely to remain stable.   
 
The Unit provides a state-wide PET imaging service for patients, and is the only PET 
unit in NSW.  Less than 20 per cent of patients scanned reside within Central Sydney 
Area Health Service.  Table 3 provides a summary of the place of residence of patients 
scanned during 1997-98. 
 Review of Positron Emission Tomography 
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TABLE 2: PATIENTS SCANNED IN THE 3 MAIN CLINICAL APPLICATIONS 1992-1999 
Year Cardiology  Neurology  Oncology  Total 
1992  (June-Dec) 9  7  7 23 
1993 64  151  220  443 
1994 52  195  528  801 
1995 43  200  853  1112 
1996 24  177  652  864 
1997 17  246  1024  1287 
1998 18  196  1114  1328 
1999 (Jan-Nov)  21  400  935  1356 
Total 248  1572  5333  7214 
 
 
TABLE 3: PLACE OF RESIDENCE OF PATIENTS SCANNED 1997-98 
Place of residence  Number of patients 
Central Sydney   206 
South Eastern Sydney  145 
Northern Sydney  198 
Western Sydney  103 
South West Sydney  154 





Mid Western  38 
New England  15 
Northern Rivers  11 
Greater Murray  18 
Southern 15 
Mid North Coast  46 
Far West  4 
Unknown 14 






3.4  Applications of PET at RPAH 
Over the period of operation of the PET Unit there has been a shift in clinical emphasis 
towards oncology, which also reflects the trend internationally in the use of PET 
imaging.  Over 80% of the throughput of the Unit is now in oncology, or more correctly 
‘surgical oncology’ particularly staging of disease.  Data from the RPA PET unit 
indicate that referrals for PET scans for patients with cancer mainly come from 
surgeons (approx 65%) and referrals from medical oncologists comprise only 14% of 
the total.  A more detailed breakdown of the uses of the PET scanner, and the cancer Viney, Lowin, Pollicino, Haywood & Fulham 
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sites is provided later in this report.  However, it should be noted that the current use of 
the scanner reflects existing knowledge of the effectiveness of PET as a diagnostic tool.  
Thus, there is an emphasis in the RPAH PET unit on lung cancer and melanoma, for 
which there is more evaluation evidence, both here and internationally.  As new 
research evidence becomes available, there may be a further shift in clinical emphasis.   
Table 4 presents a breakdown by study type of all scans undertaken in 1997-98.  
 
TABLE 4: PURPOSES OF SCAN BY STUDY TYPE 1997-98 
Study Type  Sub Area  Number of Patients 
Head Neurology   
  Brain Tumours  198 
  Degenerative 128 
   Epilepsy  81 
   Other  9 
   Normal Volunteer/Research  49 
Whole Body  Oncology   
  Lung   379 
 Melanoma  132 
 Gynaecological  34 
 Soft  Tissue  30 
 Breast  21 
 Head  and  Neck  9 
 Urogenital  9 
 Haemotological  6 
 Unknown  Primary  7 
 Other  cancers  8 
  Gastro-intestinal 170 
 Neurology  4 
Cardiology  Cardiac Viability  13 
Total   1286 
 
 
Analysis of the PET Unit database and consultation with the Director of the PET Unit 
has identified the following main applications of PET at RPAH.  These are identified in 
terms of the extent to which PET has the potential to provide additional information, 
and whether the additional information provided changes management. 
 
Neurology and Neurosurgery 
 
•  NeuroDegenerative Disorders 
The role of PET in dementia and other neurodegenerative disorders is to provide 
accurate diagnosis.  Anatomical imaging studies (Computerised Tomography & 
Magnetic Resonance imaging) are usually normal in these conditions, PET can provide 
differentiate between dementia conditions, and can provide a diagnosis premortem Review of Positron Emission Tomography 
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when anatomical imaging is unhelpful.  The principal benefit of the PET scan in this 
case is the value of the information to the individual, the referring doctor and 
carers/family members.  As treatments for dementia become available (already there are 
a number of agents that have been shown to delay the rate of disease progression in 
patients with suspected dementia in clinical trials) it is imperative that patients are 
correctly identified.  In this context a PET scan will assist in determining more 
appropriate treatment, or in limiting unnecessary investigations.  In 1997-98, 128 
patients were scanned for neurological degenerative conditions.  
 
•  Brain Tumours   
PET is used to provide information about the grade of a tumour, and to provide more 
accurate information to localise the most active tumour area for biopsy or excision by a 
neurosurgeon.  In both cases, the benefit of PET is in determining the most appropriate 
treatment, particularly surgical treatment.  Information about the grade of the tumour is 
used to determine whether patients are appropriate surgical candidates.  In 1997-98, 198 
patients were evaluated for brain tumours.  Thus, almost half of the neurological 
referrals were for evaluation of tumours. PET can also be used for the surveillance of 
low-grade brain tumours avoiding alternative methods of monitoring.  This use of PET 
may allow the earlier diagnosis of malignant transformation and earlier treatment may 
provide improved outcomes. 
 
•  Epilepsy 
PET is used in epileptic patients who have refractory focal epilepsy to localise seizure 
foci.  Thus, the PET scan may be used to provide additional diagnostic information to 
assist in management of epilepsy, in particular to select patients for whom surgery is 
likely to provide a benefit (that is, to determine whether surgery is likely to affect 
seizure control) but also to exclude patients with generalised epilepsy where surgery is 
of no benefit] and therefore to increase the probability of successful surgery.  In 1997-
98, 81 patients were scanned for epilepsy. 
 
Cardiology  
PET has been used to establish cardiac viability, to determine which patients are most 
likely to be successful candidates for revascularisation surgery.  In 1992, this 
represented approximately 30% of the workload of the PET unit, but, in line with 
research evidence, this role has changed considerably.  In 1997-98, only 13 patients Viney, Lowin, Pollicino, Haywood & Fulham 
CHERE Project Report 18 – January 2002  17
were scanned for this purpose.  The benefit of a PET scan in this case is that it 




The main role of the PET Unit at RPAH over the past six years has been in a range of 
oncology applications in the pre-surgical setting.  During 1997-98, patients were 
scanned for a range of cancers, including breast cancer, colorectal cancer, lung cancer, 
melanoma, gynaecological cancers, brain tumours and head and neck cancers.  In 
general these patients have a whole body scan, and there are a number of possible 
purposes of the scan, as outlined below. 
 
•  Lung Cancer 
PET is used to provide additional diagnostic information for patients with lung cancer.  
In 1997-98, 349 patients were referred for a whole body PET scan related to a primary 
diagnosis of lung cancer.  The majority of patients referred for a PET scan have non-
small cell lung cancer and the other large group is patients who are thought to have 
solitary pulmonary metastases from a range of malignancies including colorectal 
carcinoma, melanoma, breast cancer and soft tissue sarcomas. 
 
The main use of the PET scan is to determine whether a patient is a suitable candidate 
for surgery prior to the final decision about treatment being made. PET is used to 
determine whether patients who have been diagnosed with StageI-II non-small cell lung 
cancer on other diagnostic tests have mediastinal node involvement (Stage III) or distant 
metastatic disease (Stage IV).  Patients who have Stage III or IV cancer are generally 
not considered to be suitable candidates for surgery, although some patients with Stage 
IIIa non-small cell lung cancer may still have surgery following chemotherapy and PET 
in this instance is used to exclude Stage IV disease both before and at the completion of 
therapy.  Thus, the main benefit of PET in this case is that it may avoid unnecessary and 
potentially fatal painful surgery.  
 
PET is also used in some cases post-surgically to provide information about recurrence 
or to assess response to chemotherapy or radiotherapy.  In this case, the benefit of PET 
is that it may provide information to determine the most appropriate treatment.   
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•  Colorectal cancer 
The PET scanner can be used for the accurate staging of disease, especially in those 
who are thought to have a solitary liver metastasis that would be amenable to surgery if 
there is not more widespread disease.  This allows appropriate selection of candidates 
and enhances surgical outcomes. 
 
•  Melanoma 
The PET scanner can be used for the staging of melanoma after initial diagnosis but it is 
mainly used in patients with metastatic melanoma prior to them undergoing surgical 
intervention that may include thoracic surgery, node dissection, hepatic resection or 
craniotomy.  This may allow more appropriate treatment to be given. 
 
•  Head and Neck Cancer 
Head and Neck surgery for ontological reasons distorts the anatomy of the region.   
Because of this the more functional PET scan may be more sensitive to early local 
recurrence than more structural diagnostic tools such as CT scanners.  Early detection 
may offer more definitive and successful treatment. 
 
•  Gynaecological Cancer 
The PET scanner is being used in ovarian cancer for two purposes; one to help aid the 
diagnosis of recurrence and the second is to assess the response to chemotherapeutic 
treatment.  Earlier diagnosis of recurrence may allow improved therapeutic option 
selection.  Assessing the response to treatment of ovarian cancer to chemotherapy may 
allow the early cessation of chemotherapy in those for whom it is not affecting the 
tumour, with quality of life and resource saving implications. Viney, Lowin, Pollicino, Haywood & Fulham 




Thus, in summary, a number of potential benefits can be identified from the applications 
of PET at RPAH: 
 
•  Information for patients and clinicians 
Even where the information from a PET scan does not affect clinical management, there 
may be benefits, particularly to patients from additional diagnostic information. This is 
particularly relevant in diagnosis of dementia conditions and in patients with other 
chronic conditions where treatment does not eradicate the disease and the natural history 
of these disorders is that there is disease progression over time. 
 
•  More appropriate clinical management 
The PET scan may provide information that changes clinical management of the 
patient’s condition.  In many cases this may not provide a survival benefit (for example, 
in changed management of lung cancer), but there may be short term improvements in 
quality of life for patients, from avoidance of unnecessary surgery. However, as has 
been noted earlier, caution must be applied in assessing the extent to which PET 
changes clinical management. To evaluate this impact it is necessary to have an 
unbiased assessment of the management plan before and after the PET scan. 
 
•  Improved outcomes from treatment 
The additional diagnostic information from the PET scan may lead to more localised 
and less invasive surgery or other treatment (for example, in surgical management of 
brain tumours, colorectal cancer, melanoma).  This may improve the survival and 
quality of life outcomes from surgery. 
  
•  Resource use 
Where PET changes clinical management it may avoid unnecessary resource use, for 
example, in the case of avoiding surgery.  Whether this results in a net saving depends 
on the relative costs of the PET scan and the interventions avoided, and the proportion 
of patients for whom there is a change in management.  As in the case of changes to 
clinical management, it is difficult to assess the amount of resource savings 
retrospectively. 
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•  Allocative efficiency 
Because PET may provide information which leads to better selection of patients for 
particular interventions, it may improve the allocative efficiency of service provision. In 
particular, there are allocative efficiency gains where there are resource constraints and 
where PET provides information which leads to more accurate decisions about which 
patients are likely to benefit from treatment. However, it should be noted that there are a 
number of questions that must be addressed in assessing the value of a PET scan in 
particular clinical applications: 
 
•  Will the PET scan provide additional diagnostic information? Is the information 
from the PET scan likely to change the diagnosis? Is the information more sensitive 
and/or more specific? 
•  Will the additional diagnostic information change the choice of treatment for the 
patient?   
•  Will any change in management result in changes in survival or quality of life 
outcomes for patients? 
•  Are there any other benefits/disbenefits to patients from the additional information? 
•  Is the change in management likely to lead to a net reduction in resource use, given 
the resource use associated with undertaking the scan? 
•  Is it feasible that PET would replace another diagnostic test, or is it likely to be used 
as an adjunct to other diagnostic tests? 
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4  Estimation of the Costs of PET 
 
This section of the report outlines the methods and results of the costing undertaken for 
the PET Unit.  Costs were estimated for the 1997-98 period, because a full year of 
financial data was available.  The aims of the costing component of the project were: 
•  To estimate the total costs of the PET unit; 
•  To estimate the average cost of a PET scan; 
•  To determine whether average costs differ for different groups of patients; 
•  To estimate the short run marginal cost of a PET scan; 
•  To investigate how the costs of the PET unit would vary under different scenarios. 
 
4.1  Estimation of the Total Costs of the PET Unit for 1997-98 




•  Staff salary costs were provided from the PET unit’s accounts, with costs attributed 
to the PET unit based on information from the Director on the proportion of 
individuals’ time allocated to the PET unit (some staff are shared between Nuclear 
Medicine and the PET unit).  On costs were calculated as actual costs, again from 
the PET unit’s accounts.  On costs represent approximately 11 per cent of the total 
salary costs.  Table 5 provides a summary of the staff profile of the PET unit.  
 
TABLE 5: SUMMARY OF THE STAFF PROFILE OF THE PET UNIT 
Staff Classification  Number of Full Time Equivalents 
Scientific Officers    2.9 
Medical Radiation Technologists    2.2 
Nurse (Clinical Nurse Consultant)    1.0 
Clerical     1.5 
Cleaners   0.5 
Medical (Registrar)    1.0 
Medical (Senior Staff Specialist)     0.85 
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•  Goods and services costs were provided from the PET unit’s cost centre accounts.  
These costs included costs of medical supplies (other than isotope), stationery, 
computer software support, radiation monitoring and other operational goods and 
services. 
 
•  Isotope costs were based on actual charges made by ANSTO to Royal Prince Alfred 
Hospital.  During 1997-98 177 vials of FDG-18, 10 vials of NH3 and 10 vials of 
015 were provided to the PET Unit.  Charging is on the basis of a set price per vial.   
 
•  Estimates of overhead costs were provided by the Finance Department of Royal 
Prince Alfred Hospital.  These were based on the overhead cost allocation methods 
recommended in the NSW 1997/98 Costing Standards Manual.  Overhead costs 
were estimated and attributed for Royal Prince Alfred Hospital and for Central 
Sydney Area Health Service. 
 
•  Repairs and Maintenance costs for the PET Unit were taken from two sources.   
Some maintenance costs for the Unit are separately reported in the Royal Prince 
Alfred financial accounts.  However, this does not include the total cost of 
maintenance contracts because of the financial arrangements within the hospital, 
whereby global maintenance contracts are held, and not disaggregated to separate 
clinical units.  Therefore estimates of the maintenance costs were also based on 
information provided by the Director of the PET unit and in a separate report on the 
activity of the PET Unit. 
 
Capital Costs 
•  Building costs were estimated on the basis of an equivalent rental cost for the floor 
space occupied by the PET Unit.  This was based on commercial rents for the area, 
of $225 per square metre (this was the mid point of estimates provided by local 
commercial real estate agents).  The total floorspace of the PET unit was 311 square 
metres.  
 
•  Information on the costs of capital equipment for the operation of the PET unit was 
provided by the Director of the PET Unit and from NSW Department of Health 
files.  This included the original purchase of the PET scanner and the refurbishment Viney, Lowin, Pollicino, Haywood & Fulham 
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of the PET unit (this cost was covered by ANSTO), but does not include the cost of 
construction of the cyclotron.  The information provided was the best estimate of the 
original purchase price and the date of purchase for each item of capital equipment.  
The GDP implicit price deflator was used to convert the purchase price to 1997-98 
dollars.  It was assumed that the useful life of computer hardware was 5 years, and 
the useful life of other capital equipment was 10 years, and that there would be no 
residual value.  Using these assumptions and a discount rate of 5%, an equivalent 
annual cost of capital equipment was calculated.  
 
Table 6 summarises the total costs of the PET Unit for 1997-98.  The total costs for the 
1997-98 financial year were $2.5 million.  
 
TABLE 6: TOTAL COSTS FOR THE PET UNIT 1997-98 
Resource Item  Total Costs 1997-98 
Recurrent    
Staff $630,270   
Isotope $647,700   
Goods and Services (other)  $57,143   
Repairs and Maintenance  $226,633   
Overheads $183,401   
Total Recurrent   $1,745,147 
Capital    
Building $69,975   
Equipment $686,649   
Total Capital   $756,624 
Total   $2,501,771 
 
 
4.2  Estimation of the Average Costs per Patient for the PET Unit 
During 1997-98, 1287 patients were scanned.  Thus, the overall average cost per patient 
scanned was $1944. However, this is the average cost estimated across all scans and not 
taking account of differences in the resource use between different types of scans.   It is 
possible to provide a more detailed assessment of the average costs of scanning 
particular groups of patients, based on patient-level information from the PET Unit data 
base, which includes information such as the total time for a scan, the amount of 
isotope.  Costs were attributed to patients as outlined below. 
 
Staff costs 
Costs for those staff involved in the overall administration of the unit were averaged 
across all patients scanned during the year.  This included costs for medical staff, the 
clinical nurse consultant, and administrative and cleaning staff.  This allocation of costs Review of Positron Emission Tomography 
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was made on the basis that where these staff were involved in direct patient care, the 
resource use was not likely to substantial vary with the nature of the scan and the length 
of time for the scan. 
Costs for other staff, directly involved in scanning the patients were attributed to each 
patient on the basis of the total time for the scan.   
 
Other recurrent costs 
Isotope costs were calculated on a per patient basis, although this involves averaging 
across patients as follows. While the pet unit is charged a fixed amount for a vial of 
isotope, the amount of isotope in a vial is variable.  Thus, in practice the per patient cost 
of isotope will vary on a daily basis, depending on the amount of isotope produced.  
However, as this variability in cost cannot be predicted, in calculating a cost per patient, 
an effective price per unit of isotope (measured in megabecs) was estimated over the 
whole year, and this was used to attribute costs to patients based on the amount of 
isotope the patient received.  
 
Other goods and services were averaged across all patients scanned during the year, on 
the basis that the amount of consumables did not vary with the length of time for a scan 
or the nature of the scan. 
 
Overhead costs were averaged across all patients, on the basis that these costs cover 
items of resource use which do not vary with the nature of the scan or the length of time 
for the scan. 
 
Repairs and maintenance costs were attributed to patient on the basis of the total time 
for the scan.  This reflects the fact that the majority of these costs relate to upkeep of the 




Capital costs were attributed to patients based on the total time for the scan.  This 
reflects the fact that the opportunity cost of additional time spent scanning a patient is 
the time forgone scanning additional patients.    
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Table 7 provides a summary of the average costs for different groups of patients.  As 
would be expected, the most costly scans are whole body scans, because they require 
more time and more isotope to provide a full image of the body.  A whole body scan 
generally requires 8 ‘beds’ to complete the study (one ‘bed’ represents approximately 
10 cm). 
  
TABLE 7 AVERAGE COST OF A PET SCAN BY TYPE OF SCAN 
Type of scan     1997/1998  1998/1999
1 1999/2000
1 
All Scans    $1,944 $1,994  $2,040 
Whole Body    $1,963 $2,013  $2,060 
   Lung  $1,975  $2,026  $2,072 
   Melanoma  $2,106  $2,160  $2,210 
   Gynaecological  $1,929  $1,978  $2,024 
   Soft Tissue  $1,869  $1,917  $1,961 
   Breast  $1,981  $2,032  $2,079 
   Head and Neck  $2,086  $2,139  $2,189 
   Urogenital  $1,949  $1,999  $2,045 
   Haemotological  $2,036  $2,088  $2,136 
   Unknown Primary  $1,889  $1,937  $1,982 
   Other cancers  $2,076  $2,129  $2,178 
   Gastro-intestinal  $1,841  $1,888  $1,932 
   Neurological  $1,755  $1,800  $1,841 
            
Head    $1,856 $1,904  $1,947 
   Brain Tumours  $1,681  $1,724  $1,764 
   Degenerative  $1,842  $1,889  $1,933 
   Epilepsy  $1,815  $1,862  $1,904 
   Other  $1,852  $1,899  $1,943 
   Normal Volunteer/ 
Research 
$2,664 $2,732  $2,795 
            
Cardiology  Cardiac Viability  $3,900 $4,000  $4,092 
1. Average costs have been re-estimated for the 1998-1999 and1999-2000 period using 
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5. Conclusion 
 
This report evaluated the clinical uses, impacts on clinical management, clinical 
outcome and resource use of Positron Emission Tomography (PET) at Royal Prince 
Alfred Hospital in Sydney.  
 
A current literature review emphasised the increasing role PET scanning in oncology 
diagnosis and management.  However, the clinical studies and economic evaluations of 
this role are limited and not generaliseable to the Australian context.  To date, studies 
have focused on determining the accuracy of PET as a diagnostic tool.  Few studies 
have incorporated assessment of how PET affects clinical decision making or impact on 
patient outcomes and resource use. 
  
Since the introduction of the PET unit at RPA in 1992, throughput has increased three 
fold from 443 patients in 1993 to1328 patients in 1998. Consistent with international 
trends, the use of the PET scanner at RPA has shifted towards oncology applications, 
namely lung cancer, colorectal cancer and melanoma.   
 
The total cost of the PET unit for the 1997-98 financial year was reported at $2,501,771. 
The average cost per patient scan was approximately $1,950.  At a more detailed level, 
average costs were found to vary by type of scan with cardiology scans ($3,900) found 
to be more expensive than whole body ($1,963) and neurology scans ($1,856).  The 
high relative neurology scan cost was partially attributed to the relatively expensive 
normal volunteer/research neurology scans.  The increasing trend towards oncological 
scans may result in a decrease in the number of patients scanned as the demand for 
whole body scans increases. 
 
Further evaluation of the activity of the PET unit at RPAH is necessary. In part this 
requirement will be fulfilled by the results of the randomised controlled trial currently 
being conducted on the role of PET in management of patients with Non-Small Cell 
Lung Cancer.  However, it can also be supplemented by further analysis of existing 
throughput. Such analysis can only be undertaken when the appropriate data become 
available.  
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